BioSpace News Archive

Feb. 19, 2020 12:30 UTC AlloVir to Present at the SVB Leerink 9 th Annual Global Healthcare Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that its Chief Executive Officer, David Hallal will present at the 9th annual SVB Leerink Global Healthcare Conference on Tuesday February 25th at 2:00 PM ET at the Lotte New York Palace in New York City. AlloVir, an ElevateBio portfolio company, is the leader in the

Feb. 19, 2020 12:30 UTC Primary and secondary endpoints met in both TRuE-AD1 and TRuE-AD2 WILMINGTON, Del.--( BUSINESS WIRE )-- Incyte (Nasdaq:INCY) today announced that the second randomized, vehicle-controlled, pivotal Phase 3 study from the TRuE-AD clinical trial program has met its primary endpoint. Building on the previously-reported positive topline results from TRuE-AD2, the results of TRuE-AD1 also show that significantly more patients treated with ruxolitinib

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET-105 product candidate, which is currently under review with the U.S. Food and Drug Administration (FDA).

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces interim data from its ongoing Phase II TACTI-002 study.

-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in preclinical models to inhibit the activity of TORC1 and induce autophagy in neuronal cells --

Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB Leerink Global Healthcare Conference

Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated agreements (the “Purchase Agreements”) with a limited number of holders of Assertio’s currently outstanding 2.50% Convertible Notes due 2021 and 5.00% Convertible Senior Notes due 2024 (the “Purchased Notes”).

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of allowance from the European Patent Office (EPO) covering the use of Todos’ proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs).

LifeOmic, the creator of the LIFE mobile apps and the Precision Health Cloud (PHC) platform in use at major medical and cancer centers, today announced Ed Simcox as its new chief strategy officer.

Blue Cross Blue Shield of Massachusetts named six substance use treatment and recovery centers in its network as Blue Distinction® Centers for Substance Use Treatment and Recovery – a new designation under the Blue Distinction Specialty Care program.